XALATAN® becomes first Prostaglandin Glaucoma eye drop approver as first line therapy in Europe

Prescription medication completes mutual recognition process
Wins UK authorization

Peapack, NJ (April 23, 2002) — Pharmacia Corporation (NYSE: PHA) announced
today that the company has successfully completed the Mutual Recognition Process in
Europe for the use of XALATAN® (latanoprost ophthalmic solution) as a first line
treatment for lowering elevated intraocular pressure (IOP) in patients with open-angle
glaucoma and ocular hypertension. The new indication means the prescription eye drop
XALATAN can be used in Europe as initial treatment in place of older prescription eye
drops, such as beta-blockers. XALATAN is the only prostaglandin glaucoma medication
with first line status in Europe. Regulatory authorities in Sweden recently approved
XALATAN for first line use under a separate application. Xalatan is also approved as first
line glaucoma therapy in Japan.

The UK Medicines Control Agency is acting as the Reference Member State for XALATAN,
where the product was first licensed six years ago for patients with elevated IOP not
adequately controlled with other medicines. National approvals for use of XALATAN as first
line treatment are expected in all EU member states.

“Gaining mutual recognition for XALATAN first line in Europe is further evidence that
XALATAN is emerging as a new standard in glaucoma therapy,” said Paul Chaney, Vice
President, Global Ophthalmology Business, Pharmacia. “Now doctors in Europe will have
the option of prescribing once-daily XALATAN instead of a beta blocker as initial
monotherapy treatment. This is good news for the estimated four to five million glaucoma
patients in Europe, because once-daily XALATAN has unsurpassed efficacy and can be
prescribed for patients with cardiovascular or cardiopulmonary conditions, unlike some
older glaucoma medicines.”

When introduced in Europe in 1996 as a second-line therapy, XALATAN was the first
prostaglandin-based medicine to treat elevated IOP in patients with open-angle glaucoma
and ocular hypertension. Over time, XALATAN increasingly became an important
therapeutic alternative to older medications, particularly for patients with asthma or heart
conditions in whom beta-blocker eye drops are contraindicated and those with an IOP not
adequately controlled by other medications.

Pharmacia Corporation manufactures XALATAN® (latanoprost ophthalmic solution), the
worlds number one brand of glaucoma medication (based on market share). XALATAN is
available in more than 50 countries, with more than 300 peer-reviewed published papers
and 74 million prescriptions written worldwide. In the United States, XALATAN is indicated
for the reduction of elevated IOP in patients with open-angle glaucoma and ocular
hypertension who are intolerant of other IOP-lowering medications or insufficiently
responsive (failed to achieve target IOP determined after multiple measurements over time)
to another IOP-lowering medication. The most commonly reported side effects in eyes of
patients treated with XALATAN for six months in clinical studies include blurred vision,
burning and stinging, eyelid redness, the feeling that something is in the eye, eye itching,
darkening of eye color and irritation of the clear front part surface of the eye. XALATAN
can slowly darken eye color in the treated eye by increasing the amount of brown color
and can darken eyelids and increase the growth of eyelashes; these changes can be
permanent.

Physicians or pharmacists who have clinical questions about XALATAN, and consumers
who would like additional information on XALATAN, can call Pharmacia Corporation at 1-
800-323-4204.

Pharmacia (NYSE: PHA) is a top-tier global pharmaceutical company with a leading
agricultural subsidiary. Pharmacia's innovative medicines and other products save lives and
enhance health and wellness. Pharmacia's 59,000 people work together with many diverse
stakeholders to bring these benefits to people around the world, and to create new health
solutions for the future.

XALATAN® is a registered trademark of Pharmacia Corporation.
Pharmacia Corporation Website: www.pharmacia.com
XALATAN Website: www.xalatan.com

Media Contact: Analyst Contact:
Rosemarie Yancosek Linda C. Heller
908-901-8517 908-901-8853
908-313-4896 (cell)

לאתר חברת פרמציה – להודעות הדובר